Regulatory uniQure sets course to US filing for Huntington gene therapy PharmaphorumShares in uniQure have rocketed this morning, as it emerges that the FDA will not require it to run a new trial of Huntington's gene therapy AMT-130.NeuroscienceRead full story pharminent June 17, 2026 (Last updated: June 18, 2026) Pharmaphorum Shares in uniQure have rocketed this morning, as it emerges that the FDA will not require it to run a new trial of Huntington’s gene therapy AMT-130. Neuroscience Read full story Post navigation Previous: Jazz orchestrates a $4bn cancer alliance with AbCelleraNext: UniQure to file gene therapy for approval, reflecting major shifts at FDA Related Stories Regulatory Scholar Rock’s muscle-targeting SMA therapy Isemblyd lands FDA approval pharminent September 14, 2026 Regulatory Psychedelic therapies ride wave of public favor into FDA hearing pharminent September 14, 2026 Regulatory Bayer’s Hyrnuo set for the NSCLC frontlines on accelerated FDA label expansion pharminent September 10, 2026